Skip to main content
OpenTrials
Completed

NCT Number: NCT06687187

Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients

A study comparing the effect of two doses of neostigmine on the gastric residual volume in critically ill patients on enteral feeding.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Al-Azhar faculty of medicine

Cairo, 12546, Egypt

About this study

Participants were categorized into three groups: Group I and Group II received neostigmine 1 mg and 2 mg, respectively, and a control group received 10 ml of normal saline. All participants received an intravenous administration of 10 mg of metoclopramide. GRV was measured every 3 hours before enteral feeding. aspiration through nasogastric (NG) or orogastric (OG) tubes was done before the next due bolus of feeding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with a GRV >120ml
  • a normal heart rateExclusion Criteria
  • absence of comorbidities such as diabetes and renal failure. exclusion Criteria:
  • Patients exhibiting new-onset arrhythmias or heart block
  • hypotension (systolic blood pressure less than 60 mmHg)
  • experiencing active gastrointestinal bleeding or receiving prokinetic medications 8-12 hours before the intervention
  • patients with a history of surgery in the gastrointestinal system in the past two weeks history of extrapyramidal manifestations
  • patients with electrolyte imbalance
  • pregnant patients,

Treatment and study plan

Neostigmine

Drug

two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively

Primary outcomes

  1. The risk of aspiration

    Time frame: december 2022 to may 2024

    The risk of aspiration in ICU patients on enteral feeding via vaso-gastric or oro-hastric tubes

Sponsors and collaborators

Lead sponsor

Zulekha Hospitals

Other

Registry information

Official study title

Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients Under Enteral Feeding; a Comparative Controlled Randomized Trial

Acronym: Gastric

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 13, 2024
Registry last updated
Nov 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.